GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » Deferred Tax

Balaxi Pharmaceuticals (NSE:BALAXI) Deferred Tax : ₹0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Balaxi Pharmaceuticals Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Balaxi Pharmaceuticals's change in deferred tax for the three months ended in Dec. 2023 was ₹0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0 Mil.

Balaxi Pharmaceuticals Deferred Tax Historical Data

The historical data trend for Balaxi Pharmaceuticals's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balaxi Pharmaceuticals Deferred Tax Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only - - - - -

Balaxi Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Balaxi Pharmaceuticals Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balaxi Pharmaceuticals Deferred Tax Related Terms

Thank you for viewing the detailed overview of Balaxi Pharmaceuticals's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Balaxi Pharmaceuticals (NSE:BALAXI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » Deferred Tax
Comparable Companies
BOM:500259 BOM:524717 BOM:532890 BOM:540679 BOM:524663 BOM:511509 BOM:526139 BOM:542910 BOM:514336 BOM:539206 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 2nd Floor, Hyderabad, TG, IND, 500 096
Website
https://www.balaxipharma.in
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Substantial revenue is generated from the pharmaceutical segment division from generic drugs. Geographically it earns key revenue from Angola.

Balaxi Pharmaceuticals (NSE:BALAXI) Headlines

No Headlines